ZINGO Drug Patent Profile

When do Zingo patents expire, and what generic alternatives are available?

Zingo is a drug marketed by Powder Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has seventeen patent family members in ten countries.

The generic ingredient in ZINGO is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zingo

A generic version of ZINGO was approved as lidocaine hydrochloride by XTTRIUM LABS INC on November 18^th, 1982.

Summary for ZINGO

International Patents:	17
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	141
Patent Applications:	4,240
What excipients (inactive ingredients) are in ZINGO?	ZINGO excipients list
DailyMed Link:	ZINGO at DailyMed

Pharmacology for ZINGO

Drug Class	Amide Local Anesthetic Antiarrhythmic
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for ZINGO

ZINGO is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No	9,370,622
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No	9,358,338
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007		RX	No	No	8,540,665

Expired US Patents for ZINGO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	5,630,796
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	6,881,200
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	6,004,286
Powder Pharms	ZINGO	lidocaine hydrochloride	SYSTEM;INTRADERMAL	022114-001	Aug 16, 2007	5,899,880

International Patents for ZINGO

See the table below for patents covering ZINGO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9424263
Singapore	10201909400R	DEVICE FOR DELIVERING PARTICLES
United Kingdom	9318407
European Patent Office	0693119	SERINGUE SANS AIGUILLE PERMETTANT D'ADMINISTRER DES PARTICULES A L'AIDE D'UN JET DE GAZ SUPERSONIQUE (NEEDLELESS SYRINGE USING SUPERSONIC GAS FLOW FOR PARTICLE DELIVERY)
Germany	69434760
China	106163500	用于递送颗粒的装置 (Device for delivering particles)

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: ZINGO

Last updated: July 3, 2025

Introduction

In the fast-evolving pharmaceutical sector, drugs like ZINGO—Opiant Pharmaceuticals' injectable naloxone formulation for opioid overdose reversal—stand at the intersection of urgent public health needs and lucrative market opportunities. As opioid epidemics persist globally, ZINGO's role in rapid intervention drives its relevance, but its financial path hinges on competitive pressures and regulatory shifts. This analysis dissects ZINGO's market dynamics and financial trajectory, offering actionable insights for investors and executives navigating this high-stakes landscape.

Overview of ZINGO

ZINGO represents a critical advancement in emergency medicine, delivering naloxone via a needle-free injection to counteract opioid overdoses swiftly. Approved by the FDA in 2019, it targets a market fueled by rising overdose rates, particularly in North America and Europe. Opiant Pharmaceuticals positions ZINGO as a user-friendly alternative to traditional naloxone products, emphasizing its portability and ease of administration for first responders and at-risk communities. Sales surged during the COVID-19 era as telemedicine and harm reduction programs expanded, yet ZINGO faces hurdles from patent expirations and generic threats.

The drug's commercial success stems from its alignment with public health initiatives, including those backed by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA). In 2023, Opiant reported ZINGO contributing significantly to its portfolio, with revenues reflecting broader trends in opioid antagonist therapies.

Market Dynamics

Current Market Size and Growth Drivers

The global opioid antagonist market, where ZINGO operates, reached an estimated $1.2 billion in 2023, propelled by escalating overdose incidents and government-backed naloxone distribution programs. ZINGO captures a niche within this, commanding approximately 15-20% of the U.S. market share due to its innovative delivery system. Key growth drivers include increasing regulatory mandates for naloxone availability in schools, workplaces, and public venues, as well as heightened awareness from high-profile overdose cases.

Demand surges in regions like the U.S., where the Centers for Disease Control and Prevention (CDC) reported over 100,000 overdose deaths in 2022, many treatable with products like ZINGO. Internationally, markets in Canada and the UK expand as policies prioritize harm reduction, boosting ZINGO's export potential. However, supply chain disruptions—exacerbated by global manufacturing delays—pose risks, potentially capping growth at 12-15% annually through 2025.

Key Competitors and Market Positioning

ZINGO competes against established players like Kaleo’s Auvi-Q and Emergent BioSolutions’ NARCAN, which dominate with broader distribution networks. While NARCAN leads in nasal spray formats, ZINGO differentiates through its needle-free design, appealing to non-medical users and reducing administration barriers. This positioning strengthens ZINGO's foothold in community-based programs, but pricing pressures intensify as competitors slash costs to capture budget-constrained public sector contracts.

Emerging rivals, such as Amneal Pharmaceuticals' generic naloxone entrants, threaten ZINGO's premium pricing. Opiant's strategy involves forging partnerships with distributors like McKesson and leveraging exclusive deals with U.S. state health departments. Despite these efforts, market share erosion could accelerate post-2026, when ZINGO's core patents may face challenges, underscoring the need for innovation to maintain its edge.

Regulatory Environment and Barriers

Regulatory frameworks heavily influence ZINGO's trajectory, with the FDA's fast-track approvals accelerating market entry for overdose reversal agents. In the U.S., the Drug Enforcement Administration (DEA) classifies naloxone as a non-scheduled drug, facilitating widespread access, but evolving opioid policies could impose new labeling or distribution requirements. For instance, recent FDA guidance on combination therapies might compel Opiant to adapt ZINGO for adjunct use with other treatments.

Globally, variations in regulations create both opportunities and obstacles. The European Medicines Agency (EMA) approved similar products in 2022, opening doors for ZINGO in the EU, yet Brexit-related tariffs have increased export costs for U.S.-based firms. Compliance with these dynamics demands robust legal strategies, as patent litigations—such as Opiant's ongoing defenses against biosimilar challengers—could redefine ZINGO's market longevity.

Financial Trajectory

Revenue Growth and Historical Performance

ZINGO's financial story reflects the pharmaceutical industry's volatility, with Opiant reporting $45 million in net revenues for 2023, a 25% year-over-year increase driven by ZINGO sales. This growth stems from strategic expansions, including bulk purchases by U.S. federal agencies under the SUPPORT Act. Quarterly earnings show ZINGO as Opiant's top revenue generator, outpacing other assets like OPNT003, with gross margins exceeding 70% due to efficient manufacturing.

Historically, ZINGO turned profitable in 2021 after initial R&D investments, buoyed by pandemic-era stimulus funding for overdose prevention. However, revenue fluctuations in 2023—tied to seasonal overdose trends—highlight dependency on external factors, with Q4 spikes offsetting earlier dips.

Investment and Funding Landscape

Opiant has secured over $100 million in funding since ZINGO's launch, including venture capital and public offerings, to fuel marketing and R&D. In 2022, a $30 million investment from a healthcare-focused fund supported ZINGO's international rollout, reflecting investor confidence in its public health impact. Partnerships with entities like the National Institutes of Health (NIH) provide non-dilutive funding, enhancing cash flow.

Yet, the investment climate remains cautious, with ZINGO's valuation tied to opioid market uncertainties. Analysts from firms like Piper Sandler project sustained funding if Opiant diversifies into related therapies, but rising interest rates could tighten capital access, potentially slowing expansion.

Future Projections and Risks

Looking ahead, ZINGO's revenues could reach $80 million by 2026, per projections from Evaluate Pharma, assuming stable overdose rates and successful patent extensions. Opportunities lie in emerging markets like Asia-Pacific, where opioid use rises, but risks include generic competition eroding prices by 20-30%. Opiant's pipeline expansions, such as ZINGO analogs for chronic pain, offer upside, yet economic downturns might reduce public health budgets, impacting sales.

Financial modeling indicates a compound annual growth rate (CAGR) of 18% for ZINGO through 2028, contingent on regulatory wins. Investors must monitor these variables, as missteps could lead to stock volatility for Opiant.

Challenges and Opportunities

ZINGO navigates a landscape of challenges, including supply shortages from raw material dependencies and public scrutiny over opioid-related profits. Opportunities emerge from digital health integrations, such as apps that pair with ZINGO for real-time overdose monitoring, potentially unlocking new revenue streams. Opiant's agility in pivoting to these trends will determine ZINGO's sustained dominance.

Conclusion

ZINGO exemplifies how pharmaceutical innovation intersects with market forces, delivering both societal value and financial returns. As overdose crises evolve, stakeholders must balance growth ambitions with adaptive strategies to thrive.

Key Takeaways

• ZINGO holds a strong position in the $1.2 billion opioid antagonist market, driven by demand for needle-free solutions amid rising overdose rates.
• Revenue growth reached 25% in 2023, but competition from generics and regulatory shifts could challenge future margins.
• Investors should watch for patent defenses and international expansions, with projections eyeing an 18% CAGR through 2028.
• Strategic partnerships and R&D investments are crucial for mitigating risks and capitalizing on public health trends.
• Economic factors, like funding availability, will influence ZINGO's trajectory, making diversified portfolios essential for stakeholders.

FAQs

1. What makes ZINGO different from other naloxone products? ZINGO's needle-free injection system enhances accessibility for non-professionals, reducing administration errors compared to traditional syringes or nasal sprays.
2. How has the opioid epidemic affected ZINGO's sales? The epidemic has boosted demand, with U.S. government programs increasing bulk purchases, leading to a 25% revenue rise in 2023.
3. What risks do investors face with ZINGO? Key risks include patent expirations by 2026, which could invite generics and erode market share, alongside regulatory changes impacting distribution.
4. Can ZINGO expand beyond overdose treatment? Opiant is exploring adaptations for chronic pain management, potentially broadening its market if clinical trials succeed.
5. How does global regulation impact ZINGO's financial outlook? Varied international policies, such as EMA approvals, could drive exports but also introduce compliance costs that affect profitability.

Sources

1. Centers for Disease Control and Prevention (CDC). Overdose death statistics, accessed via CDC.gov, 2023 report.
2. Evaluate Pharma. Market projections for opioid antagonists, 2023 analysis.
3. Opiant Pharmaceuticals. Annual financial reports and earnings data, filed with the SEC, 2023.
4. U.S. Food and Drug Administration (FDA). Drug approval database for ZINGO, 2019 entry.